



Local bio-clinical protocol for other organ transplantation (liver, heart, lung ...) v.2

The recommendations of the kidney/pancreas protocol apply, but since liver, heart and lung transplants may be urgent, it is accepted that the patient's file may be incomplete prior to transplantation.

1. Sampling.

The Clinical Department ensures that:

- samples are drawn by qualified and authorized personnel in accordance with regulations.
- the pre-analytical conditions comply with the procedures described in the sampling manual of the performing LBM.
- each sample is accompanied by the examination request form designed by the executing LBM, duly completed.

Failure to comply with these requirements will result in sample rejection.

2. HLA Typing

For the recipient and the selected donor, 2 HLA typings are mandatory and obtained from 2 separate samples, before transplant.

The second typing results confirm the first one and the identity of the patient.

The techniques used will be different for the 2 typings:

- low-resolution typing A B DRB1 DQB1,
- high-resolution typing A, B, C, DRB1 (+DRB3/4/5), DQA1, DQB1, DPA1 and DPB1.

The donor should be typed on all loci to which the recipient is immunized, at the resolution necessary to conclude on the presence of preformed DSA.

The laboratory can conclude on the HLA compatibility between the recipient and the donor and recipient if both typings are available.



3. Patient immunological record, HLA immunization, histocompatibility tests

The CERBA laboratory does not carry out research/identification of anti-HLA antibodies, nor does it perform real or virtual cross-match tests.

The patient's immunological record is kept by the clinical department.

The transplant physician assumes responsibility for the transplant, with the complete histocompatibility profile established for the recipient.

4. References.

EFI standards for histocompatibility and immunogenetics testing, current version.

RECOMMENDATIONS OF THE FRENCH SOCIETY OF TRANSPLANTATION (SFT) AND THE FRENCH SOCIETY OF HISTOCOMPATIBILITY AND IMMUNOGENETICS (SFHI) FOR HLA TYPING AND PRE- AND POST-RENAL TRANSPLANT MONITORING OF ANTI-HLA ANTIBODIES (Version 31/10/2019)

Date and signatures:

CERBA

TRANSPLANT DEPARTMENT

(department, hospital, city, country)

TRANSPLANT DEPARTMENT SIGNATORY

(surname,first name, qualification)